Related Experiment Video
Updated: Aug 15, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells
Yongfa Li1, Shenghu Zhang2, Min Peng3
1Department of Oncology, Xinkang Hospital of Renmin Hospital of Wuhan University, Wuhan, 430000, Hubei, P.R. China.
Background:
Altered platinum chemotherapy sensitivity is a major determinant of treatment outcome in ovarian cancer; however, the molecular mechanisms underlying adaptive chemotherapy responses remain incompletely understood. Sphingomyelin synthase 1 (SMS1) and sphingomyelin synthase 2 (SMS2), key enzymes involved in sphingomyelin biosynthesis, have been implicated in cancer biology, but their roles in platinum chemotherapy response remain unclear.
Methods And Results:
SMS1 and SMS2 expression was evaluated in ovarian cancer cells following chemotherapy exposure. Gain- and loss-of-function approaches were used to investigate their effects on cell proliferation, apoptosis, and chemotherapy sensitivity, while biochemical assays were performed to explore underlying mechanisms. Cisplatin selectively induced SMS1, but not SMS2, expression at both mRNA and protein levels in a dose- and time-dependent manner. Silencing of either SMS1 or SMS2 inhibited cell growth, promoted apoptosis, and enhanced sensitivity to cisplatin and paclitaxel. However, only SMS1 overexpression consistently protected cells against cisplatin- and paclitaxel-induced apoptosis. Mechanistically, SMS1 depletion caused lysosomal impairment, increased lipid peroxidation, and enhanced lysosome-associated oxidative injury, whereas SMS2 depletion induced oxidative stress-related alterations without a clearly defined dominant downstream mechanism. Importantly, multiple platinum agents, including cisplatin, carboplatin, and oxaliplatin, selectively induced SMS1 expression, and SMS1 depletion enhanced sensitivity to platinum-based chemotherapy. Clinical survival analysis further revealed that high SMS1 expression was associated with poorer outcomes, particularly in patients receiving Taxol plus platinum-based chemotherapy.
Conclusions:
SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. SMS1 functions as a platinum-induced adaptive resistance factor by maintaining lysosomal homeostasis and supporting tumor cell survival. Disrupting SMS1-mediated adaptation may represent a potential strategy to enhance platinum chemotherapy efficacy. Although SMS2 contributes to chemotherapy response, its downstream mechanisms remain to be further elucidated.
Insights
Sphingomyelin synthase 1 (SMS1) helps ovarian cancer cells resist platinum chemotherapy by maintaining lysosomal function. Targeting SMS1 could improve treatment effectiveness against ovarian cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Platinum chemotherapy resistance is a key challenge in ovarian cancer treatment.
- The role of sphingomyelin synthases (SMS1 and SMS2) in chemotherapy response is not well understood.
Purpose of the Study:
- To investigate the roles of SMS1 and SMS2 in platinum chemotherapy sensitivity in ovarian cancer.
- To explore the molecular mechanisms by which SMS1 and SMS2 affect chemotherapy response.
Main Methods:
- Assessed SMS1 and SMS2 expression in ovarian cancer cells after chemotherapy exposure.
- Utilized gain- and loss-of-function studies to evaluate effects on cell proliferation, apoptosis, and chemotherapy sensitivity.
- Performed biochemical assays to elucidate underlying mechanisms.
Main Results:
- Cisplatin selectively increased SMS1 expression, while SMS1/SMS2 silencing enhanced sensitivity to cisplatin and paclitaxel.
- SMS1 overexpression protected cells from apoptosis, linked to lysosomal impairment and oxidative injury.
- High SMS1 expression correlated with poorer patient outcomes, especially with Taxol plus platinum chemotherapy.
Conclusions:
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer.
- SMS1 acts as a platinum-induced resistance factor, supporting tumor cell survival via lysosomal homeostasis.
- Targeting SMS1 may enhance platinum chemotherapy efficacy in ovarian cancer.
Related Concept Videos
Treatment Resistant Cancers
Abnormal Proliferation

